Specialty Pharmacy

Alexander Spira, MD, PhD, FACP, discussed how there are many types of malignancies when it comes to lung cancer, and we need to set this paradigm for our patients in the future.

The Alliance for Pharmacy Compounding created the tool to help address a need for drugs to treat patients with COVID-19.

According to the results of a nationwide survey conducted among clinical pharmacists, too many working hours is the major factor causing burnout, followed by inadequate management.

The current state of oncology is shaping challenges for the future specifically in the areas of telehealth, home infusions, and a surge of new patients that have not been to oncology clinics yet.

Experts discuss what their teams have learned throughout the COVID-19 pandemic, during the COA virtual conference.

Solving challenges of the current system is vital to spreading clinical trials into community clinics, which may be increasingly important.

Pharmacy adjudication systems vary among specialty pharmacies and many limitations still exist across most providers in the market.

New research has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.

Former NFL quarterback and Pro Football Hall of Fame member Jim Kelly announced as a keynote speaker for the 2020 NASP Annual Meeting & Expo.

Shivani Patel, RPh, SVP, Clinical Operations and Technology, Asembia discusses the use of digital tools to better connect industry leaders and health care professionals.

Sacituzumab govitecan-hziy is the first antibody-drug conjugates approved by the FDA specifically for relapsed or refractory metastatic triple-negative breast cancer (TNBC).

Implementation of adherence programs can be effective in improving outcomes for patients and reduce costs both at the patient and systemic level.

Using CRISPR technology, researchers conducted a study aimed at identifying genes that fuel leukemia growth, in order to find new vulnerabilities in chronic myeloid leukemia that can be targeted.

An analysis has shown that aspirin is associated not only with a significant reduction in the risk of developing several cancer types.

Cancer cells avoid an immune system attack after radiation by taking control of a cell signaling pathway that helps dying cells avoid triggering an immune response.

Patients with BRAF mutations administered treatment with encorafenib/binimetinib trended toward improved and longer responses than patients who received dabrafenib/trametinib.

In preliminary data from the trial evaluating dostarlimab, the results demonstrated that the clinical activity in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer had an acceptable safety profile.

The new expanded approval was based on positive results from the phase 3 E1912 study.

Treatment of ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors has a high out-of-pocket cost for patients, with substantial variation among them, according to a study.

A phase 3 trial evaluated nivolumab in combination with ipilimumab in patients with previously untreated MPM and successfully met its primary endpoint of overall survival.

Purdue University researchers have created technology that uses optical imaging to better help surgeons map out tumors in the body and understand how certain diseases affect activity in the brain.

Over the past 20 years, the specialty pharmacy channel has been the fastest growing segment of pharmacy practice.

Oncology/Hematology pharmacists from Boston Medical Center discuss how COVID-19 has affected their patients.

An interview with Debra Richardson, MD, examined the phase 2 study that included niraparib with bevacizumab for patients with either a complete or partial response after upfront chemotherapy for advanced ovarian cancer.

A protein secreted by fat cells may link obesity and breast cancer, according to a newly published article inTrends in Molecular Medicine.

A new study revealed that researchers have found a genetic test that could help doctors determine which patients with multiple myeloma are at “ultra high risk” of their cancer progressing aggressively in its early stages.

The FDA has granted accelerated approval to pemigatinib (Pemazyre, Incyte Corporation) as the first treatment for adults with certain types of previously treated, advanced cholangiocarcinoma.

This approval is a part of the first Project Orbis partnership between the FDA, Health Sciences Authority, and Swissmedic.

A protein, known as FOXO1, plays a critical role in heart damage resulting from treatment with the chemotherapy drug anthracycline.

N95 respirators can be decontaminated effectively and maintain functional integrity for up to 3 uses, according to a study by the National Institutes of Health (NIH).